Kusajili – Clinical trials directory

Result of your search per sponsor: Pierre Fabre Ibérica, S.A. en representación de Pierre Fabre Mèdicament

Woman Max 99 years
Pierre Fabre Ibérica, S.A. en representación de Pierre Fabre Mèdicament Update Il y a 4 ans

Phase II trial of oral vinorelbine in combination with capecitabine and trastuzumab as first line therapy in women with previously untreated HER2 positive metastatic breast cancer To evaluate the Overall Response Rate (ORR) of oral vinorelbine (Navelbine Oral) in combination with capecitabine (Xeloda) and i.v. trastuzumab (Herceptin) for HER2 positive patients.

Country None
organs None
Specialty None

unknown

More information